Scios And Medtronic To Develop Heart Failure Treatment

. has announced its entry into a research collaboration with Medtronic, Inc. to study the effects of Scios’ investigational agent Natrecor (nesiritide) in combination with Medtronic’s heart failure devices and implantable infusion systems.

“We are excited to establish this collaboration as both Scios and Medtronic have a shared commitment to the diagnosis and management of heart failure in all of its manifestations,” said Scios Chief Scientific Officer George F. Schreiner, M.D., Ph.D. “This research effort between the two companies explores the potential for new heart failure treatments combining Natrecor’s unique therapeutic properties with Medtronic’s approach to the treatment of heart failure.”

In the first of a planned program of pilot clinical studies, the hemodynamic and clinical effects of Natrecor, including the effects on spontaneous activity and controlled exercise tolerance, will be evaluated using information collected by Medtronic’s Chronicle Implantable Hemodynamic Monitor (IHM) both during and after infusions of Natrecor.

The pilot feasibility study is expected to begin this quarter at the Karolinska Hospital in Stockholm.

Both Natrecor and the Chronicle IHM are currently under clinical investigation in the United States.

Natrecor is currently being reviewed by the U.S. FDA as a potential treatment for acute CHF. If approved for marketing by the FDA, Natrecor would be the first new treatment available for acute CHF in over a decade.

The Chronicle system is being studied in a worldwide multicenter clinical trial.

Medtronic expects to file for U.S. and European marketing approvals for this system by the end of this year.

Scios is a biopharmaceutical company developing novel treatments for cardiovascular and inflammatory diseases.

The company’s disease-based technology platform integrates expertise in protein biology with combinatorial and medicinal chemistry to identify novel targets and rationally design large and small-molecule compounds to treat cardiovascular and inflammatory diseases, two of the world’s leading unmet medical needs.

Obtain Dragon Pharma On-line


Selective Estrogen Receptor Modulator
Primary Constituent: Tamoxifen Citrate
Branded by: Dragon Pharmaceuticals
Package: 1 X 100 pastilles (20 mg/pill)

Trenbolone 100 - Cheap Price

Administration: Injection
Primary Component: Trenbolone Acetate
Manufacturer: Dragon Pharmaceuticals
Pack: 20 x 10 mL vial (100 mg/mL)
Price: 20 x $52.00

Turanabol - Bulk Price

Administration: Oral
Base Substance: Chlorodehydromethyltestosterone
Producer: Dragon Pharmaceuticals
Amount: 10 x 100 tablets (10 mg/tablet)
Price: 10 x $70.00

Cypionat 250 - Bulk Price

Administration: Injection
Basic Ingredient: Testosterone Cypionate
Made by: Dragon Pharma Labs
Amount: 10 x 10 mL vial (250 mg/mL)
Price: 10 x $36.00

Masteron 100

Injectable Steroid for Muscle Growth
Prime Substance: Drostanolone Di-Propionate
Produced by: Dragon Pharma LLC
10 mL Sterile Multi-dose Vial (100 mg/mL)

Trenbolone 50

Injectable Steroid for Muscle Growth
Principal Constituent: Trenbolone Suspension
Produced by: Dragon Pharma Labs
10 mL Sterile Multi-dose Vial (50 mg/mL)

Primobolan 100 [10 Vials]

Injectable Steroid for Muscle Growth
Active Ingredient: Methenolone Enanthate
Producer: Dragon Pharma
10 Vials [10 mL per Vial (100 mg/ml)]
Price: 10 x $75.00 = $750.00 in Total

Sustanon 350

Prime Ingredient: Testosterone Blend
Manufacturer: Dragon Pharmaceutical
Unit: 10 mL vial (350 mg/mL)

TriTren 150

Basic Ingredient: Tri Trenbolone
Producer: Dragon Pharmaceuticals
Amount: 10 x 10 mL vial (150 mg/mL)


Basic Substance: Clenbuterol Hydrochloride
Branded by: Dragon Pharma Labs
Amount: 100 pastilles (40 mcg/pastille)

Masteron 200

Injectable Anabolic Steroid
Base Chemical Name: Drostanolone Enanthate
Producer: Dragon Pharma LLC
Unit: 10 mL vial (200 mg/mL)

Masteron 100 Cheap Price

Branded by: Dragon Pharmaceutical
Active Constituent: Drostanolone Di-Propionate
Unit: 10 x 10 mL vial (100 mg/mL)
Amount Price: 49.00 USD